FM101 is a selective adenosine A3 receptor modulator developed for various indications, including glaucoma and non-alcoholic fatty liver disease.[1][2][3]
References edit
- ^ Jayanetti, Viran; Sandhu, Sartaj; Lusthaus, Jed A. (20 November 2020). "The Latest Drugs in Development That Reduce Intraocular Pressure in Ocular Hypertension and Glaucoma". Journal of Experimental Pharmacology. 12: 539–548. doi:10.2147/JEP.S281187. PMC 7685378. PMID 33244278.
- ^ Park, JeongSu; Choi, Su-Yeon; Wang, Feng; Park, Chong-Woo; Lee, Jiyoun; Lee, Hyuk-Woo; Roh, Yoon-Seok (April 2020). "Imbalance Between α1-Antitrypsin and Neutrophil Elastase in Simple Steatosis Promotes Inflammation and Fibrosis Through Regulation of Adenosine a3 Receptor Signaling in Non-alcoholic Steatohepatitis". The FASEB Journal. 34 (S1): 1. doi:10.1096/fasebj.2020.34.s1.03837. S2CID 219099467.
- ^ Park, Chong-Woo; Han, Chung-Tack; Sakaguchi, Yasue; Lee, Jiyoun; Youn, Hwa-young (12 February 2020). "Safety evaluation of FM101, an A3 adenosine receptor modulator, in rat, for developing as therapeutics of glaucoma and hepatitis". EXCLI Journal. 19: 187–200. doi:10.17179/excli2019-2058. ISSN 1611-2156. PMC 7105940. PMID 32256265.